Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tominersen Open-Label Extension in Huntington's Disease
NCT03342053Phase 2Completed
- Sponsor
- Roche
- Start
- Jan 2018
- Primary completion
- Oct 2019
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 3
01
Overview
A Phase 2 trial of tominersen in Huntington's disease (HD), sponsored by Roche. Started Jan 2018; status: completed.
02
Drugs
tominersen
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT03342053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03342053.